Sharemaestro Newsreel

VSee Signs LOI for $42 Million Healthcare Platform Acquisition

VSee Health Inc. (NASDAQ: VSEE) has signed a non-binding letter of intent to acquire a vertically integrated healthcare commerce platform for approximately $42 million. This acquisition is expected to add over $35 million in annualized revenue and about $7 million in EBITDA, significantly expanding …

GUIDANCE: (OMCL) Omnicell, Inc. Expects Q3 Adjusted EPS Range $0.35 - $0.43

Omnicell, Inc. (OMCL) has issued guidance for its third-quarter adjusted EPS, anticipating a range of $0.35 to $0.43. This guidance provides investors with an outlook on the company's expected financial performance for the upcoming quarter.

Teladoc Stock Plummets on Revenue Miss, Lowered Outlook

Teladoc Health Inc (NYSE:TDOC) saw its shares plunge by 22% after reporting second-quarter revenues that missed Wall Street estimates and subsequently lowering its full-year guidance. Despite a smaller-than-expected loss per share, investors reacted negatively to slowing growth in its BetterHelp mental health segment. The …

Omnicell Announces Second Quarter 2026 Financial Results

Omnicell, Inc. reported solid financial results for the second quarter of 2026, with total revenues of $312 million, a 7% increase from the previous year. The company saw a significant improvement in GAAP net income and non-GAAP net income per diluted share, partly due …

Tempus AI, Inc. Class A (TEM) Q4 2024 Earnings Report - Results, Call & Slides

Tempus AI, Inc. (TEM) released its Q4 2024 earnings report, showing a miss on both EPS and revenue expectations. The company reported an actual EPS of -$3.12 against a consensus of -$2.71, and actual revenue of $3.48 billion against an expected $3.52 billion. The …

Proposed VSee Health Deal Would Add $35M Annual Run Rate

VSee Health (NASDAQ: VSEE) has entered into a non-binding letter of intent to acquire healthcare technology and operating assets for approximately $42 million. This acquisition is projected to add over $35 million in unaudited annual revenue run rate and about $7 million in EBITDA. …

VSee Health enters letter of intent for $35M acquisition By Investing.com

VSee Health Inc. announced it has entered into a non-binding letter of intent to acquire specific healthcare technology and operating assets. These assets operate an integrated healthcare commerce platform catering to the U.S. clinic-based wellness market, with current unaudited annual run rates exceeding $35 …

VSee Enters into Letter of Intent to Acquire Vertically Integrated Healthcare Commerce Platform - Acquisition, Valued at $42Million, Would Add over $35Million in Annualized Revenue and More than $7Million in Earnings

VSee Health, Inc. has signed a non-binding letter of intent to acquire certain healthcare technology and operating assets for $42 million. This acquisition is expected to add over $35 million in annualized revenue and approximately $7 million in EBITDA. The transaction aligns with VSee's …

DarioHealth launches integrated GLP-1 program with clinical care

DarioHealth Corp. has launched an Integrated GLP-1 Program, developed in collaboration with Beluga Health, which integrates licensed provider evaluations, FDA-approved GLP-1 medication prescribing, and clinical oversight with Dario's existing chronic care platform. The program aims to address the growing demand for GLP-1 treatments, with …

Mangoceuticals (MGRX) plans Nuclea merger, 96% new-owner stake, $15M PIPE

Mangoceuticals (MGRX) has announced a Business Combination Agreement with Nuclea Energy Inc. through which Nuclea shareholders will own approximately 96% of the combined entity on a fully diluted basis before PIPE financing, with existing Mangoceuticals stockholders retaining about 4%. The transaction involves a two-stage …

Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance

Omnicell (NASDAQ:OMCL) reported Q2 CY2026 earnings, beating Wall Street's revenue and EPS estimates with sales up 7.4% year-on-year to $312.2 million and non-GAAP EPS of $0.94. Despite the Q2 beat and raised full-year EBITDA and EPS guidance, the stock dropped 5.6% due to weaker-than-expected …

Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates

Omnicell (OMCL) reported Q2 earnings of $0.94 per share, significantly exceeding the Zacks Consensus Estimate of $0.48, and revenues of $312.21 million, also topping estimates. Despite these strong results, Omnicell shares have fallen 8.6% year-to-date, contrasting with the S&P 500's 6.9% gain. The company …

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BE

Mangoceuticals to Combine With Nuclea Energy; Nuclea Holders to Own ~96% Pre-PIPE

Mangoceuticals (MGRX) has entered into a Business Combination Agreement with Nuclea Energy, utilizing a Canadian exchangeable-share structure. Upon closing, Nuclea shareholders will receive exchangeable shares in a Mango subsidiary, which can be exchanged for Mango common stock. Former Nuclea holders are expected to own …

Mangoceuticals Deal Would Put Nuclea's ~3.5-50 MWe Reactor on Nasdaq Path

Mangoceuticals (NASDAQ: MGRX) has signed a definitive business combination agreement with Nuclea Energy, a Canadian developer of the lead-cooled Morpheus microreactor, to advance next-generation nuclear microreactor technology. The deal is structured to provide Nuclea a Nasdaq listing and offer Mangoceuticals shareholders exposure to the …

Jacob D. Cohen to Leave CEO Role at Mangoceuticals, Becomes President in Consulting Role

Jacob D. Cohen, CEO of Mangoceuticals (MGRX), will step down from his CEO role upon the closing of a transaction, transitioning instead to President in an independent consulting capacity. New executive officers will be appointed by the Principal Nuclea Shareholders, and existing executives not …

Why is Omnicell stock rallying today?

Omnicell stock initially surged after reporting strong Q2 2026 earnings, significantly beating analyst estimates for both EPS and revenue. However, the rally was short-lived as the company's Q3 and full-year guidance fell below market expectations, leading to a subsequent pullback and erasing most of …

Earnings Flash (OMCL) Omnicell, Inc. Posts Q2 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.47

Omnicell, Inc. (OMCL) announced its Q2 adjusted earnings per share (EPS) of $0.94, significantly surpassing the FactSet estimate of $0.47. The company's Q2 revenue also exceeded expectations, reporting $312.2 million against an estimated $310.2 million. Omnicell further provided a Q3 revenue outlook ranging from …

Omnicell (NASDAQ: OMCL) Q2 profit jumps as 2026 guidance raised

Omnicell (NASDAQ: OMCL) reported strong second-quarter 2026 results, with total revenues up 7% to $312 million and GAAP net income increasing to $24 million. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance and tightened its revenue outlook. The positive results …

Schrodinger Inc (SDGR) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Schrodinger Inc (SDGR), which currently has a risk assessment score of 5.38 and a beta of 1.61. The report details various financial metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different periods. It also touches …

Teladoc Health Q2 Loss Widens, Revenue Falls; 2026 Guidance Updated

Teladoc Health Inc. reported a widening loss and a decrease in revenue for its second quarter of 2026, compelling the company to update its full-year 2026 guidance. This financial performance has led to a tumble in Teladoc's stock, primarily due to shifts in demand …

SLP|Simulations Plus Inc|Price:18.340|Chg%:+0.010

TradingKey provides a comprehensive stock analysis for Simulations Plus Inc (SLP), highlighting its healthy fundamentals, high growth potential, and current "Hold" rating from analysts with an average target price of $19.83. Despite a recent turnaround to a loss, the company's valuation is considered fairly …

Vsee Health Inc (VSEE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vsee Health Inc (VSEE), focusing on its price momentum, support, resistance levels, and various technical indicators and moving averages. As of July 29, 2026, VSEE has a price momentum score of 5.52, ranking 70th in its industry, …

Teladoc Health sinks 21% after mixed quarter and soft outlook (TDOC:NYSE)

Teladoc Health (TDOC) shares dropped 21% in premarket trading after reporting a mixed quarterly performance and issuing a Q3 outlook that missed Wall Street expectations. The company's CEO, Charles Divita, indicated that advertising spending for 2026 is now expected to be lower than previously …

Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.84, Implies 15% Downside

Teladoc Health, Inc.'s average 12-month price target has modestly increased to $7.84 from $7.76, based on estimates from 19 analysts, with a range of $5 to $11. This updated target suggests a potential 15% downside from its July 29 closing price. The consensus rating …

Waystar (WAY) Stock Price Reset Follows Margin Strength And Slower Organic Growth

Waystar Holding Corp. (WAY) experienced a 14.6% stock price drop despite reporting strong Q2 2026 earnings with expanding profitability and a 43% adjusted EBITDA margin. While the company's AI-led platform narrative shows growth in subscription revenue and larger client contracts, organic revenue growth lags …

Sophia Genetics SA (SOPH) Financial Health: Profitability & Balance Sheet Analysis

Sophia Genetics SA (SOPH) currently holds a financial score of 6.49, placing it 348th out of 485 in the Software & IT Services industry. The company's financial status is stable, though its operating efficiency is low. In its latest quarter, Sophia Genetics SA reported …

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

Mangoceuticals, Inc. (NASDAQ: MGRX) has announced a definitive business combination agreement with Nuclea Energy Inc., a developer of advanced nuclear microreactor technology. This reverse merger will allow Nuclea to access public markets, aiming to capitalize on the increasing demand for continuous, carbon-free power driven …

BrightSpring Health Services (BTSG) To Report Earnings Tomorrow: Here Is What To Expect

Omnicell Q2 2026 Revenue Rises 7 Percent to $312 Million

Analysts Estimate Definitive Healthcare Corp. (DH) to Report a Decline in Earnings: What to Look Out for

CareCloud (CCLD) to Release Earnings on Thursday

Teladoc (TDOC) Stock Plummets on Disappointing Q2 Earnings Results

Teladoc Health (NYSE: TDOC) Q2 2026 shows revenue dip and weaker BetterHelp

Privia Health Group (PRVA) to Announce Quarterly Earnings on Thursday

Veeva (VEEV) Stock May Be 30% Undervalued As Cash Flows Hold Up